Salah Mahmoudi

#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team.     In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo    #biotechnews #fundraising #venturecapital #oncology #lungdiseases

51

Lead optimization is recognized as a highly complex and costly phase in antibody discovery. To improve lead quality, many labs are establishing early developability screenings. Back in 2017, the well-known PNAS paper by Jain et al. generated a lot of interest. Their team characterized 137 clinical stage mAbs using a dozen different biophysical methods, aiming to improve lead selection. However, no clear consensus emerged within the scientific community regarding which assays are most critical, prompting companies to develop their own individual strategies. When we speak with our users today, we observe broad agreement that hydrophobic interaction chromatography (HIC) and self-association assays (such as AC-SINS) are generating valuable data. There is also increasing recognition of Heparin binding as a potential predictor of PK. But when it comes to polyspecificity, things get murkier. Many existing assays rely on complex preparations from baculovirus or membrane proteins, which suffer from batch-to-batch variability, or ELISA assays, which are inconsistent due to the multiple washing steps involved. While many in the industry recognize these limitations, they often find themselves without viable alternatives, as none of these assays are available as reliable commercial products. We at PAIA aim to fill that gap by offering a growing range of developability assay kits. They feature no-wash protocols and use simple, chemically defined reagents, providing a more reliable way to generate critical biophysical data. #developability #antibodydiscovery #leadoptimization #screening

18

1 Comment

Single-cell technologies and their comparison...

1